Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.

Purpose: In absence of specific dosing guidelines, the optimal dose of low molecular weight heparins for thrombosis prophylaxis in morbidly obese patients (BMI > 40 kg/m) remains unknown. In order to guide dosing in this patient group, a pharmacodynamics model is developed for nadroparin in morbidly...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 71; no. 1; pp. 25 - 35
Main Authors:	Diepstraten, Jeroen, Janssen, Esther, Hackeng, Christian, Dongen, Eric, Wiezer, René, Ramshorst, Bert, Knibbe, Catherijne
Format:	equations & formulas research tables/charts Journal Article
Published:	Springer Nature Jan2015
Online Access:	View this record in EBSCOhost